Relationships Between Glymphatic System Activity and Tau Burden, Dopaminergic Impairment, Abnormal Glucose Metabolism in Progressive Supranuclear Palsy
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70284 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Fangyang Jiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine & PET Center, National Clinical Research Center for Aging and Medicine & National Center for Neurological Disorders, H…. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive, Glymphatic System, tau Proteins, Glucose. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Industrial Collaborative Innovation Project, National Natural Science Foundation of China, STI2030-Major Projects.
Abstract (Originalsprache)
Background
Progressive supranuclear palsy (PSP) is a primary tauopathy characterized by dopaminergic impairment and abnormal glucose metabolism. The glymphatic system can promote the elimination of tau protein. The association between glymphatic function and pathological hallmark in neuroimaging remains unknown.
Methods
Diffusion tensor imaging (DTI) and positron emission tomography (PET) scanning with 18 F‐Florzolotau, 18 F‐FPCIT, and 18 F‐FDG were performed in PSP patients. DTI analysis along the perivascular space (ALPS) index was computed to assess glymphatic function, while the semi‐quantitative value was employed to measure tau burden and dopaminergic impairment. The PSP‐related pattern (PSPRP) served as an indicator of abnormal metabolic brain network activity.
Results
PSP patients exhibited changes in ALPS index and tau deposition. ALPS index, tau deposition, and PSPRP expression showed significant correlations with clinical scores. Additionally, ALPS index was correlated with tau deposition and PSPRP expression. However, neither ALPS index nor the clinical scores were correlated with striatum dysfunction. Finally, tau deposition in subcortical regions and PSPRP expression exhibited mediating effects between ALPS index and clinical scores.
Conclusion
The glymphatic dysfunction is associated with tau deposition and abnormal metabolic brain network activity and is independent of dopaminergic impairment in PSP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine & PET Center, National Clinical Research Center for Aging and Medicine & National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
- Institute of Biomedical Engineering, School of Life Science, Shanghai University, Shanghai, China.
- Department of Neurology, National Clinical Research Center for Aging and Medicine & National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Fangyang Jiao, Jiaying Lu, Jiehui Jiang
Förderung
- Shanghai Industrial Collaborative Innovation Project
- National Natural Science Foundation of China
- STI2030-Major Projects
Zitieren
APA
Jiao, F., Wang, Q., Zhong, J., Lin, H., Lu, J., Wang, L., Wang, M., Liu, F., Jiang, J., & Zuo, C. (2025). Relationships Between Glymphatic System Activity and Tau Burden, Dopaminergic Impairment, Abnormal Glucose Metabolism in Progressive Supranuclear Palsy. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70284
Vancouver
Jiao F, Wang Q, Zhong J, Lin H, Lu J, Wang L, et al. Relationships Between Glymphatic System Activity and Tau Burden, Dopaminergic Impairment, Abnormal Glucose Metabolism in Progressive Supranuclear Palsy. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70284
BibTeX
@article{Jiao2025,
author = {Jiao, Fangyang and Wang, Qingmin and Zhong, Jiayi and Lin, Huamei and Lu, Jiaying and Wang, Luyao and Wang, Min and Liu, Fengtao and Jiang, Jiehui and Zuo, Chuantao},
title = {Relationships Between Glymphatic System Activity and Tau Burden, Dopaminergic Impairment, Abnormal Glucose Metabolism in Progressive Supranuclear Palsy},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70284}
}
EUVIMED